Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. This phase II trial is studying how well panobinostat works in treating patients
with relapsed or refractory non-Hodgkin lymphoma